CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms

被引:3
|
作者
Chen, Xin [1 ]
Guo, Chuangen [2 ]
Cui, Wenjing [1 ]
Sun, Ke [3 ]
Wang, Zhongqiu [1 ]
Chen, Xiao [1 ]
机构
[1] Nanjing Univ Chinese Med, Affiliated Hosp, Dept Radiol, Nanjing 2100029, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Radiol, Hangzhou 310003, Zhejiang, Peoples R China
[3] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China
来源
关键词
pancreatic neuroendocrine neoplasm; grade; pancreatic neuroendocrine carcinoma; CD56; CHROMOGRANIN-A; GRADE; 3; TUMOR; CARCINOMA;
D O I
10.2147/CMAR.S250071
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: CD56 is a neural cell adhesion molecule that plays a role in the cohesiveness of neuroendocrine cells. The aim of this study was to explore the biological values of CD56 expression in pancreatic neuroendocrine neoplasms (PNENs) and its role in predicting PNENs grades. Patients and Methods: A total of 138 patients with histological-proven PNENs was included (66 G1, 46 G2 and 26 G3). The clinicopathological characteristics, including mitosis count, ki67 index, chromogranin A (CgA), synaptophysin (Syn) and CD56 expression, were evaluated. We assessed the diagnostic performance of markers in predicting PNEN G3 and the association between CD56 expression and risk of G3 or organs invasion. Results: Lack of CD56 immunoreaction (CD56-) was more common in PNEN G3 than G1/G2 (31% vs 0-2%, p < 0.01). The sizes of CD56- tumors were larger than CD56 positive tumors in PNEN G3 (p < 0.01). The odds ratio (OR) of CD56- expression was 13.6 [95% confidence interval (CI): 2.1-88.1] in predicting PNEN G3. The OR of CD56- expression was 6.5 (95% CI: 1.1-38.6) and 31.9 (95% CI: 1.09-938.3) in predicting organs invasion and neuroendocrine carcinoma in PNEN G3, respectively. Tumor size (area under the curve [AUC] = 0.77 and size+CD56- expression [AUC = 0.84]) had acceptable performance in predicating PNEN G3. Conclusion: Lack of CD56 immunoreaction may be a predictor and biological behavior marker for PNEN G3.
引用
收藏
页码:4625 / 4631
页数:7
相关论文
共 50 条
  • [21] Comparison of CD56 expression in osseous and extraosseous plasmacytomas
    Sun, XL
    Tsao, L
    Bhagat, G
    Alobeid, B
    MODERN PATHOLOGY, 2005, 18 : 252A - 252A
  • [22] The impact of CD56 expression in smoldering Multiple Myeloma
    Notarfranchi, Laura
    Vescovini, Rosanna
    Segreto, Roberta
    Bonomini, Sabrina
    Storti, Paola
    Marchica, Valentina
    Sammarelli, Gabriella
    Todaro, Giannalisa
    Soressi, Naomi
    De Giovanni, Dario
    Burroughs-Garcia, Jessica
    Toscani, Denise
    Palma, Anna Benedetta Dalla
    Giuliani, Nicola
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S111 - S111
  • [23] Aberrant CD56 expression in primary cutaneous plasmacytoma
    Galan, A.
    Milstone, E.
    Subtil, A.
    JOURNAL OF CUTANEOUS PATHOLOGY, 2008, 35 (01) : 154 - 154
  • [24] THE ROLE OF CD56 EXPRESSION IN SMOLDERING MULTIPLE MYELOMA
    Notarfranchi, L.
    Storti, P.
    Vescovini, R.
    Segreto, R.
    Bonomini, S.
    Sammarelli, G.
    Todaro, G.
    Raimondi, V.
    Burroughs-Garcia, J.
    Toscani, D.
    Dalla Palma, A. B.
    Giuliani, N.
    HAEMATOLOGICA, 2022, 107 : 44 - 44
  • [25] Characterization of CD56 (NCAM) in paraffin-embedded tissue: A potentially useful marker for neuroendocrine neoplasms and peripheral nerve.
    Shipley, WR
    Hammer, R
    Macon, WR
    Lennington, WJ
    LABORATORY INVESTIGATION, 1996, 74 (01) : 1024 - 1024
  • [26] Microvillous lymphomas are B-cell neoplasms that frequently express CD56
    Hammer, RD
    Vnencak-Jones, CL
    Manning, SS
    Glick, AD
    Kinney, MC
    MODERN PATHOLOGY, 1998, 11 (03) : 239 - 246
  • [27] Acute myeloid leukemia (AML) with CD56 expression - A very high incidence of CD56 expression in AML with t(8;21) in Taiwan.
    Hsiao, CH
    Tang, JL
    Yao, M
    Tsay, W
    Wang, CH
    Chen, YC
    Shen, MC
    Tien, HF
    BLOOD, 2000, 96 (11) : 190B - 191B
  • [28] CD200 Expression in Neuroendocrine Neoplasms
    Love, Jason E.
    Thompson, Kimberly
    Kilgore, Mark R.
    Westerhoff, Maria
    Murphy, Claire E.
    Papanicolau-Sengos, Antonios
    McCormick, Kinsey A.
    Shankaran, Veena
    Vandeven, Natalie
    Miller, Faith
    Blom, Astrid
    Nghiem, Paul T.
    Kussick, Steven J.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 148 (03) : 236 - 242
  • [29] Expression of CD56 in patients with adenomyosis and its correlation with dysmenorrhea
    Wang, Fei
    Shi, Xixi
    Qin, Xiaoyan
    Wen, ZeQing
    Zhao, Xingbo
    Li, Changzhong
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 194 : 101 - 105
  • [30] Aberrant NK cell associated marker (CD56 and CD57) expression in chronic lymphocytic leukemia
    Dorwal, Pranav
    Mehra, Simmi
    Pande, Amit
    Jain, Dharmendra
    Smeeta, G.
    Sachdev, Ritesh
    Raina, Vimarsh
    CYTOMETRY PART B-CLINICAL CYTOMETRY, 2015, 88 (05) : 348 - 351